Information Provided By: 
Fly News Breaks for June 2, 2015
MRK, BMY
Jun 2, 2015 | 08:21 EDT
Cowen said its takeaway from the ASCO conference was that Bristol-Myers (BMY) remains a stock to own while there is no need to own Merck (MRK). The firm believes Merck's monotherapy trial will look good, but is unsure of its commercial impact, while Bristol-Myers' trials make it well positioned in three major tumor areas. Cowen reiterated its Outperform rating and $75 price target on Bristol-Myers and a Neutral rating and $62 price target on Merck.
News For BMY;MRK From the Last 2 Days
